ARway.ai Issues Stock Options
ARway.ai, an AI-powered Augmented Reality Experience platform (CSE:ARWY, OTCQB:ARWYF, FSE:E65), has announced the issuance of stock options to key personnel. The company has granted 50,000 two-year stock options at $0.055 per share to new board member Peter Bloch, 500,000 two-year stock options at $0.055 per share to CFO Anum Wagas, and 50,000 two-year stock options at $0.055 per share to board member Anthony Pizzonia.
Peter Bloch brings significant experience as a CPA, CA, with a history of building technology companies, particularly in life sciences. His previous roles include CEO positions at BresoTEC and Bionik Laboratories, and CFO positions at several major companies including Sanofi Canada, Intellivax, and Just Energy.
ARway.ai, una piattaforma di Esperienza in Realtà Aumentata supportata dall'IA (CSE:ARWY, OTCQB:ARWYF, FSE:E65), ha annunciato l'emissione di opzioni azionarie per il personale chiave. L'azienda ha concesso 50.000 opzioni azionarie di due anni a $0.055 per azione al nuovo membro del consiglio Peter Bloch, 500.000 opzioni azionarie di due anni a $0.055 per azione al CFO Anum Wagas e 50.000 opzioni azionarie di due anni a $0.055 per azione al membro del consiglio Anthony Pizzonia.
Peter Bloch porta con sé un'esperienza significativa come CPA, CA, con una storia di costruzione di aziende tecnologiche, in particolare nel settore delle scienze della vita. Le sue posizioni precedenti includono ruoli di CEO presso BresoTEC e Bionik Laboratories, e ruoli di CFO in diverse grandi aziende, tra cui Sanofi Canada, Intellivax e Just Energy.
ARway.ai, una plataforma de Experiencias de Realidad Aumentada impulsada por IA (CSE:ARWY, OTCQB:ARWYF, FSE:E65), ha anunciado la emisión de opciones sobre acciones para personal clave. La empresa ha otorgado 50,000 opciones sobre acciones a dos años a $0.055 por acción al nuevo miembro de la junta Peter Bloch, 500,000 opciones sobre acciones a dos años a $0.055 por acción al CFO Anum Wagas y 50,000 opciones sobre acciones a dos años a $0.055 por acción al miembro de la junta Anthony Pizzonia.
Peter Bloch aporta una experiencia significativa como CPA, CA, con un historial en la creación de empresas tecnológicas, especialmente en ciencias de la vida. Sus roles anteriores incluyen posiciones como CEO en BresoTEC y Bionik Laboratories, y CFO en varias grandes empresas, incluidas Sanofi Canadá, Intellivax y Just Energy.
ARway.ai는 AI 기반의 증강 현실 경험 플랫폼(CSE:ARWY, OTCQB:ARWYF, FSE:E65)으로, 핵심 인력에게 주식 옵션을 부여한다고 발표했습니다. 회사는 새로운 이사회 멤버인 Peter Bloch에게 50,000개의 2년 만기 주식 옵션을 주당 $0.055에, CFO Anum Wagas에게 500,000개의 2년 만기 주식 옵션을 주당 $0.055에, 그리고 이사회 멤버인 Anthony Pizzonia에게 50,000개의 2년 만기 주식 옵션을 주당 $0.055에 부여했습니다.
Peter Bloch는 CPA, CA로서의 경험이 풍부하며, 특히 생명 과학 분야에서 기술 회사를 세운 경력이 있습니다. 그의 이전 역할에는 BresoTEC와 Bionik Laboratories의 CEO직과 Sanofi Canada, Intellivax, Just Energy와 같은 몇몇 대기업에서의 CFO직이 포함됩니다.
ARway.ai, une plateforme d'Expérience de Réalité Augmentée propulsée par l'IA (CSE:ARWY, OTCQB:ARWYF, FSE:E65), a annoncé l'émission d'options d'actions pour le personnel clé. L'entreprise a accordé 50 000 options d'actions sur deux ans à 0,055 $ par action à Peter Bloch, nouveau membre du conseil, 500 000 options d'actions sur deux ans à 0,055 $ par action à la CFO Anum Wagas, et 50 000 options d'actions sur deux ans à 0,055 $ par action au membre du conseil Anthony Pizzonia.
Peter Bloch possède une expérience significative en tant que CPA, CA, avec un parcours dans la création d'entreprises technologiques, notamment dans le domaine des sciences de la vie. Ses précédents postes incluent des fonctions de PDG chez BresoTEC et Bionik Laboratories, ainsi que des postes de CFO dans plusieurs grandes entreprises, y compris Sanofi Canada, Intellivax et Just Energy.
ARway.ai, eine KI-gestützte Plattform für Augmented Reality Experiences (CSE:ARWY, OTCQB:ARWYF, FSE:E65), hat die Gewährleistung von Aktienoptionen an Schlüsselpersonen bekannt gegeben. Das Unternehmen hat 50.000 zweijährige Aktienoptionen zu je $0,055 pro Aktie an das neue Vorstandsmitglied Peter Bloch, 500.000 zweijährige Aktienoptionen zu je $0,055 pro Aktie an CFO Anum Wagas und 50.000 zweijährige Aktienoptionen zu je $0,055 pro Aktie an Vorstandsmitglied Anthony Pizzonia vergeben.
Peter Bloch bringt umfangreiche Erfahrung als CPA, CA mit sich und hat eine Geschichte im Aufbau von Technologieunternehmen, insbesondere im Bereich der Lebenswissenschaften. Zu seinen früheren Positionen zählen CEO-Ämter bei BresoTEC und Bionik Laboratories sowie CFO-Positionen bei mehreren großen Unternehmen, darunter Sanofi Kanada, Intellivax und Just Energy.
- Addition of experienced board member Peter Bloch with extensive public company management experience
- Stock option grants align management interests with shareholders
- Potential dilution from issuance of 600,000 stock options
TORONTO, ON / ACCESSWIRE / January 10, 2025 / ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision announces the issuance of stock options.
ARway.ai issued Peter Bloch, a successful entrepreneur and new BOD member 50,000 2-year stock options exercisable at .055/share. The company also issued 500,000 2-year .055/share options to Anum Wagas CFO. BOD member Anthony Pizzonia was also issued 50,000 2 year stock options at .055/share.
Bio:
Peter Bloch was the Chief Executive Officer of BresoTEC Inc. Mr. Bloch was also the CEO & Chairman of Bionik Laboratories from 2012 to 2018. Mr. Bloch is a CPA, CA, with a track record of building both public and private technology companies, mainly in the life sciences industry. In these roles, Mr. Bloch has secured significant funding for both private and public companies, gained experience with initial public offerings and led a number of acquisitions and partnership transactions. His past 25 years of executive management experience includes serving as Chief Financial Officer and joint interim CEO of Sanofi Canada Inc., the Canadian affiliate of Sanofi -Aventis, a global healthcare leader; Chief Financial Officer of Intellivax Inc., a biotechnology company which was sold to GlaxoSmithKline for
Sign up for Investor News - HERE
To learn more about ARway, please follow on Social Media: Twitter, YouTube, Instagram, LinkedIn, and Facebook, and visit our website: www.arway.ai
About ARway.ai
ARway.ai (CSE: ARWY) (OTCQB: ARWYF) (FSE: E65) is a spatial computing platform powered by artificial intelligence (AI) providing an array of augmented reality (AR) experiences for indoor spaces. ARway's breakthrough no-code no-beacon IPN allows for the easy creation of navigation, tours, information sharing, notifications, advertising and gamification. ARway works seamlessly as a cross platform solution on iOS/ Android. ARway's technology is optimized for both mobile devices and AR glasses: Apple's Vision Pro, Magic Leap and Microsoft's HoloLens. ARway has unlimited use cases for augmenting physical spaces, making it a valuable tool for creators, brands and companies in various industries. The complete ARway platform includes: the Web Creator Studio, the ARwayKit Software Development Kit (SDK) and a mobile app for iOs and Android.
Nextech 3D.ai
On October 26, 2022, ARway.ai. was spun-out from its parent Company, Nextech3D.ai (OTCQX: NEXCF) (CSE: NTAR) (FSE: 1SS). Nextech retained a control ownership in ARway.ai. with 13 million shares, or a
For further information, please contact:
Investor Relations Contact
investor.relations@arway.ai
ARway.ai
Evan Gappelberg
CEO and Director
866-ARITIZE (274-8493)
Forward-looking Statements
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "will be" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. ARway.ai will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE: ARway Corporation
View the original press release on accesswire.com
FAQ
How many stock options did ARway.ai (ARWYF) issue in January 2024?
What is the exercise price of ARWYF's newly issued stock options?
What is the expiration term for ARway.ai's (ARWYF) new stock options?
What is Peter Bloch's background joining ARway.ai's (ARWYF) board?
